Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2) is a member of the NFAT transcription factor family, crucial for T-cell development and immune function. It is a DNA-binding protein that resides in the cytoplasm and translocates to the nucleus upon T-cell receptor activation, where it regulates expression of key cytokines fundamental to immune response. NFATC2 interacts with multiple cofactors and is involved in various signaling pathways, including those influencing cell migration and chondrogenesis. Genetic alterations of NFATC2, such as oncogenic fusion with EWSR1, have been implicated in certain cancers. Pharmacologically, NFATC2 is targeted indirectly by calcineurin inhibitors (cyclosporine, tacrolimus) used in transplantation and autoimmune settings, which block its activation and nuclear translocation.
Inhibition of calcineurin prevents NFATC2 dephosphorylation and nuclear translocation, blocking cytokine gene transcription (mechanism for cyclosporine and tacrolimus)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2).